Radiation Therapy in Non-small-Cell Lung Cancer

Gückenberger, Matthias; Pöttgen, Christoph; Stuschke, Martin

doi:10.1007/978-3-319-52619-5_34-1

Cited by 1 publication

(1 citation statement)

References 254 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Shortly after introduction to clinical practice in the symptomatic treatment of pain, anticancer effects were noted both empirically and by theoretical reasoning [62,63]. Celecoxib is now being widely studied and even used on and off cancer treatment protocols in a variety of different cancers [64][65][66][67][68][69][70][71]. Celecoxib has demonstrated preclinical synergy with a variety of other traditionally used cytotoxic drugs in suppressing OS growth [72][73][74][75].…”

Section: The Analgesic Celecoxibmentioning

confidence: 99%

The OSR9 Regimen: A New Augmentation Strategy for Osteosarcoma Treatment Using Nine Older Drugs from General Medicine to Inhibit Growth Drive

Kast

2023

IJMS

View full text Add to dashboard Cite

As things stand in 2023, metastatic osteosarcoma commonly results in death. There has been little treatment progress in recent decades. To redress the poor prognosis of metastatic osteosarcoma, the present regimen, OSR9, uses nine already marketed drugs as adjuncts to current treatments. The nine drugs in OSR9 are: (1) the antinausea drug aprepitant, (2) the analgesic drug celecoxib, (3) the anti-malaria drug chloroquine, (4) the antibiotic dapsone, (5) the alcoholism treatment drug disulfiram, (6) the antifungal drug itraconazole, (7) the diabetes treatment drug linagliptin, (8) the hypertension drug propranolol, and (9) the psychiatric drug quetiapine. Although none are traditionally used to treat cancer, all nine have attributes that have been shown to inhibit growth-promoting physiological systems active in osteosarcoma. In their general medicinal uses, all nine drugs in OSR9 have low side-effect risks. The current paper reviews the collected data supporting the role of OSR9.

show abstract

Section: The Analgesic Celecoxibmentioning

confidence: 99%

The OSR9 Regimen: A New Augmentation Strategy for Osteosarcoma Treatment Using Nine Older Drugs from General Medicine to Inhibit Growth Drive

Kast

2023

IJMS

View full text Add to dashboard Cite

show abstract

Radiation Therapy in Non-small-Cell Lung Cancer

Cited by 1 publication

References 254 publications

The OSR9 Regimen: A New Augmentation Strategy for Osteosarcoma Treatment Using Nine Older Drugs from General Medicine to Inhibit Growth Drive

The OSR9 Regimen: A New Augmentation Strategy for Osteosarcoma Treatment Using Nine Older Drugs from General Medicine to Inhibit Growth Drive

Contact Info

Product

Resources

About